澳大利亚体外膜氧合后6个月死亡或残疾发生率:前瞻性多中心注册队列研究
该研究在澳大利亚23家医院前瞻性纳入接受ECMO的成人患者,评估ECMO启动后6个月死亡或中重度残疾的发生率。391例有结局数据的患者中,260例(66%)发生死亡或中重度残疾,eCPR组风险高于VV-ECMO组。仅约三分之一患者存活且无中重度残疾。
要点
- ECMO后6个月死亡或中重度残疾发生率为66%(260/391)。
- eCPR组死亡或中重度残疾风险高于VV-ECMO组(RD -32%,95%CI -49至-15)。
- VA-ECMO与eCPR风险差异无统计学意义(RD -8%,95%CI -22至6)。
核心结论
- ECMO启动后6个月仅约三分之一患者存活且无中重度残疾。
- 死亡或中重度残疾在各功能领域均常见,提示需长期多学科照护。
研究设计与样本
- 前瞻性、多中心、注册嵌入队列研究,在澳大利亚23家医院开展。
- 纳入2019年2月15日至2020年12月31日期间在参与中心ICU接受ECMO的成人(≥18岁)患者。
- 442例入组患者中391例(88%)有结局数据。
主要发现
- 6个月死亡或中重度残疾共260/391例(66%)。
- VA-ECMO组136/202例(67%),VV-ECMO组60/111例(54%),eCPR组64/78例(82%)。
临床怎么用
- ECMO幸存者出院后需关注中重度残疾风险,安排长期多学科随访与支持。
- eCPR患者6个月不良结局风险较高,患者选择与ICU管理策略需综合考量。
局限性
- 需进一步研究不同诊断和不同ECMO模式患者的180天及更长期预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Extracorporeal membrane oxygenation (ECMO) is an invasive procedure used to support critically ill patients with the most severe forms of cardiac or respiratory failure in the short term, but long-term effects on incidence of death and disability are unknown. We aimed to assess incidence of death or disability associated with ECMO up to 6 months (180 days) after treatment. METHODS: This prospective, multicentre, registry-embedded cohort study was done at 23 hospitals in Australia from Feb 15, 2019, to Dec 31, 2020. The EXCEL registry included all adults (≥18 years) in Australia who were admitted to an intensive care unit (ICU) in a participating centre at the time of the study and who underwent ECMO. All patients who received ECMO support for respiratory failure, cardiac failure, or cardiac arrest during their ICU stay were eligible for this study. The primary outcome was death or moderate-to-severe disability (defined using the WHO Disability Assessment Schedule 2.0, 12-item survey) at 6 months after ECMO initiation. We used Fisher's exact test to compare categorical variables. This study is registered with ClinicalTrials.gov, NCT03793257. FINDINGS: Outcome data were available for 391 (88%) of 442 enrolled patients. The primary outcome of death or moderate-to-severe disability at 6 months was reported in 260 (66%) of 391 patients: 136 (67%) of 202 who received veno-arterial (VA)-ECMO, 60 (54%) of 111 who received veno-venous (VV)-ECMO, and 64 (82%) of 78 who received extracorporeal cardiopulmonary resuscitation (eCPR). After adjustment for age, comorbidities, Acute Physiology and Chronic Health Evaluation (APACHE) IV score, days between ICU admission and ECMO start, and use of vasopressors before ECMO, death or moderate-to-severe disability was higher in patients who received eCPR than in those who received VV-ECMO (VV-ECMO vs eCPR: risk difference [RD] -32% [95% CI -49 to -15]; p<0·001) but not VA-ECMO (VA-ECMO vs eCPR -8% [-22 to 6]; p=0·27). INTERPRETATION: In our study, only a third of patients were alive without moderate-to-severe disability at 6 months after initiation of ECMO. The finding that disability was common across all areas of functioning points to the need for long-term, multidisciplinary care and support for surviving patients who have had ECMO. Further studies are needed to understand the 180-day and longer-term prognosis of patients with different diagnoses receiving different modes of ECMO, which could have important implications for the selection of patients for ECMO and management strategies in the ICU. FUNDING: The National Health and Medical Research Council of Australia.
引用
- Hodgson CL, Higgins AM, Bailey MJ, et al. Incidence of death or disability at 6 months after extracorporeal membrane oxygenation in Australia: a prospective, multicentre, registry-embedded cohort study. Lancet Respir Med. 2022. PMID: 36174613. doi:10.1016/S2213-2600(22)00248-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。